- Case Report
- Open Access
Rapid recurrence and bilateral lungs, multiple bone metastasis of malignant solitary fibrous tumor of the right occipital lobe: report of a case and review
© Wu et al. 2015
- Received: 5 February 2015
- Accepted: 10 June 2015
- Published: 9 July 2015
Intracranial malignant solitary fibrous tumor (MSFT) is extremely rare. The authors report a case of MSFT of the right occipital lobe with a rapid recurrence and bilateral lung, multiple bone metastasis.
The patient was a 25-year-old male presenting with headache, nausea and visual disturbances without obvious cause. Three times right-side occipital craniotomies were performed and two times postoperative conformal radiotherapy were administered within one year. 4 months after the third time of right-side occipital craniotomy, the patient felt right chest pain and neck pain. Positron emission tomography/computed tomography (PET/CT) showed tumor recurrence of the right occipital lobe and bilateral lung metastasis, multiple bone metastasis including: vertebrae, libs, the left iliac wing, sacrum, the right ischium and upper parts of both femurs. Ultrasound guided puncture biopsy of left-side back of the neck and CT guided puncture biopsy of the third lumbar vertebra were performed. General sample showed grayish white or grayish red with irregular shape. Histopathologically, the tumor was composed of areas of alternating hypercellularity and hypocellularity with spindle-shaped cells, which arranged as fascicular, storiform pattern or patternless pattern, with intervening irregular eosinophilic collagen bundles. Some areas showed hemangiopericytoma-like perivascular pattern and perivascular hyalinization. Tumor cells were pleomorphic with mitotic counts of more than 4 per 10 high power fields and showed coagulative necrosis. Immunohistochemically, tumor cells were diffusely positive for vimentin and CD99, focal positive for CD34, bcl-2 and Actin. Ki-67 labelling index was more than 40 %. The final pathological diagnosis was MSFT of the right occipital lobe, metastatic MSFT of left-side back of the neck and the third lumbar vertebra.
The MSFT of the right occipital lobe with recurrence and bilateral lung, multiple bone metastasis is extremely rare. Although intracranial MSFT is extremely rare, it should be considered in the differential diagnosis. Definite diagnosis depended mainly on pathological morphology and immunohistochemistry. The prognosis of MSFT is poor due to recurrence and metastasis. Complete resection of intracranial MSFT is difficult, and carful follow-up is needed.
- Intracranial tumor
- Malignant solitary fibrous tumor
- Differential diagnosis
Clinicopathological features of intracranial malignant solitary fibrous tumors
Ng et al. 2000 
cellular pleomorphism, no mitoses in PT; 3–4 mitoses/10HPFs in RT, the same Ki-67 LI of 3 %
3 recurrences over 10years, metastasis to the soft tissues and lungs
Barron et al. 2001 
hypercellularity, marked pleomorphism, 4 mitoses/10 HPFs
10 months (postoperative radiation herapy given)
Martin et al. 2001 
dura around the sagittal sinus
marked pleomorphism, 6 mitoses /10 HPFs
death 1 month after the diagnosis
Kim et al. 2004 
hypercellularity and more than 4 mitoses/10HPFs, pleomorphism, hemorrhage, and necrosis
9 years,disseminated to the spine, lung, and liver
Miyashita et al. 2004 
the MIB-1 LI increased from less than 1 % in the PT to 13 % in the latest tumor
several recurrences over 15 years, dissemination to the cerebrospinal fluid
Ogawa et al. 2004 
Ki67 LI and mitosis rates were 3.1 ± 1.2 % and less than 1/10HPF in the PT and 16.1 ± 6.4 % and 6/10HPF in the last (5th) one
4 recurrences over 26 years, metastasis to the right lung and focal invasion into the cerebellum
Pizem et al. 2004 
dura-based, left frontal
the mitoses increased from less than 1/10HPF in the PT to 16/10HPF in the latest tumor
4 recurrences over a 30-year period
Lawlor et al. 2008 
dural-based, left parietal
invasion into the sagittal sinus, 19 mitoses/10HPFs, marked amianthoid fibre deposition
Hu et al. 2009 
dural-based, left occipital
hypercellularity, rare mitoses in PT, >20 mitoses/10 HPFs in RT
died 16 month later due to recurrence and metastasis to bilateral lungs
Zhang et al. 2010 
hypercellularity, 5 mitoses/10HPFs, and MIB-1 LI (7.3 ± 1.8 %)
10 months (postoperative radiotherapy not performed)
Choi et al. 2011 
left occipital lobe
hypercellularity, pleomorphism, Ki-67 LI increased from 10 % (average, 1 %) in PT to 25 % in RT with infiltrative brain invasion and 15 mitoses/10HPFs
recurrences over a 6-months period
Although SFT occurs mainly in the mediastinum and visceral pleura, in accordance with previous studies, approximately 30 % of SFT arise in any extrathoracic locations, including the CNS . Since the first SFT case was reported in 1931 by Klemperer and Rabin, it was not until 1996 that the first CNS SFT, located at the meninges, was identified as a distinct entity by Carneiro et al. . The exact origination of CNS SFT remained under controversy. In the CNS, SFTs are usually dura-based, meningioma-like masses and are known to arise from the ubiquitous CD34-positive dendritic interstitial cells of meningeal coverings without meningothelial differentiation . The new World Health Organization classification of tumors of the CNS includes SFT among the mesenchymal nonmeningothelial tumors. It is of interest that most intracranial SFTs seem to be dura-based, whereas two-thirds of spinal SFTs lack a dural attachment . Currently it is more inclined to consider they are derived from vascular mesenchymal cells [17, 18]. Due to the rarity of mesenchymal interstitial tissue in CNS, SFT is a rare tumor of CNS.
SFT in the CNS most occurred in the posterior fossa and spine as well as along spinal nerve rootlets . However, SFT occurrence in brain parenchymal and intraventricular locations has also been rarely described. CNS SFTs occur across all ages with a peak incidence in the fifth and sixth decades of life with near equal gender distribution. A few cases have been described in children. In the current case, the patient was a 23-year old man at the onset of disease. Clinical symptoms and signs of SFT at presentation depend on the location of the tumor and the involved organs or tissues. In Fargen’s review, most SFT in the CNS presented with headache (50 %) followed by gait imbalance (22 %), weakness (19 %), visual loss (19 %), cranial nerve dysfunction (17 %), nausea and vomiting (13 %) and altered mental status or confusion (12 %). It is noteworthy that the current patient presented with rare intracranial hemorrhage (ICH) and similar presentation only was described in 6 literatures . In addition, an association of approximately 4-5 % of pleural SFTs with Doege–Potter syndrome, a rare paraneoplastic syndrome resulting in hypoglycemia from secretion of insulin-like growth factors 2 was not reported in any CNS SFT cases [3, 15].
MSFT showed rapid local recurrence and distant metastasis. Based on the new World Health Organization (WHO) classification of tumors of the CNS published in 2007 and WHO classification of tumors of soft tissue and bone published in 2013, necessary criterions suggestive of the malignant potential of SFTs include hypercellularity, more than 4 mitoses/10 HPFs, variable cytological atypia, tumor necrosis, and/or infilitrative margins, among which mitoses seem to be most prognostic [2, 19]. Some pathologists have suggested that the size of a SFT (bigger than 10cm) is one of the best indicators of malignancy . Currently, there are no criteria for determining malignancy with tumor size in cerebral SFTs. In addition, approximately 8 % of the cases demonstrated “atypical features” based upon brain or bone invasion, marked pleomorphism or high mitotic indices . However, Fargen et al. think it is important to note that above-mentioned atypical features in no way suggest an intermediate classification of SFT between benign and malignant and may merely reflect an increased malignant potential . Even the tumor with benign histopathologic change and intact capsule may develop recurrence, malignant transformation and delayed seeding of the CSF space. While our case showed important malignant evidence such as: obviously nuclear atypia, numerous mitoses, necrosis and infiltrative margins. These histological features were consistent with MSFT.
Most intracranial SFT seem to demonstrate a dural attachment and are usually mistaken for meningioma either radiologically and surgically. Intra-parenchymal non-dural-based SFTs are extremely rare in cranial compartment. As in the current case, first postoperation histopathology revealed a spindle cell tumor, tend to be anaplastic meningioma. Therefore, it is possible that the real frequency of CNS MSFT has been underestimated.
Clinical and imaging features of CNS SFTs are relatively nonspecific and resemble to both meningiomas and hemangiopericytomas, which makes preoperative diagnosis difficult. Definite diagnosis mainly depends on careful examination of histological and immunohistochemical features. WHO classification for tumors of soft tissue treats hemangiopericytoma and SFT as a continuous spectrum of neoplasia, and many lesions that were called hemangiopericytomas prior to 1990 could now be called SFT [3, 15, 19]. Morphologically, SFT is generally characterized by alternating hypercellularity and hypocellularity with spindle cells intervening with irregular hyalinzed collagen bundles showing a pattern-less architecture and a focal hemangiopericytoma-like perivascular pattern riched in staghorn vasculature. However, our case showed mainly hypocellularity due to the nature of puncture tissue. Immunohistochemically, SFT are diffusely positive for CD34, while MSFT are weakened, patchy positive for CD34, which make it difficult to tell MSFT apart from meningiomas. CD34 is not specific for SFTs, as weak and usually patchy staining may be visualized in meningiomas, neurofibromas, and hemangiopericytomas. At this moment, combination of CD34 with CD99 and BCL-2 is necessary for differential diagnosis. Positivity for CD99 and bcl-2 is found in more than half of all cases of SFTs, and strongly stained with the Vimentin is also common. SFTs are usually negative for the S-100, GFAP, EMA, cytokeratin, or vascular antigens. Recent researches validate the diagnostic utility of a novel marker, nuclear expression of STAT6, in distinguishment of SFT from histologic mimics . Moreover, the identification of the NAB2-STAT6 fusion gene can provide important diagnostic information, even in formalin-fixed and paraffin-embedded tissue or when biopsy material is limited . In addition, compared with CD34, ALDH1 expression had a specificity and positive predictive value of 100 % for the diagnosis of SFT [22, 23].
Surgery is the preferred treatment and achieves excellent local control for SFT, however, complete resection of intracranial MSFT is difficult. The prognosis is most likely dependent upon the extent of complete resection rather than histologic grading [2, 3, 15]. Recurrence occurred commonly in cases involving incomplete excision. It is clear that gross total resection (GTR) is superior to subtotal/partial resection (STR) in treatment of CNS SFT, with a nearly 16-fold increased odds of recurrence seen in patients undergoing only STR . Hence, careful follow-up is needed, especially when GTR cannot be achieved. Some scholars suggested intraoperative pathologic examination of CNS SFTs to exclude the residual of tumor at incisal margin. In these cases, adjuvant chemotherapy or radiotherapy may play a role in prevention of recurrence. However, no studies have demonstrated the role of radiotherapy in improving long-term prognosis till now and the number of patients who underwent adjuvant chemotherapy is too small to evaluate any possible benefit . A recent study suggests that Gamma Knife radiosurgery (GKRS) is a feasible adjunct for treating SFT . The current patient exhibited malignant features regarding impossibility of complete resection, rapid recurrence, distant metastasis and histopathological changes. Unfortunately, postoperative radiotherapy is of no effect to him. Adjuvant chemotherapy had been administered to the patient after accurate diagnosis was made and treatment continues till now.
In conclusion,the authors report here a rare case of MSFT of the right occipital lobe with a rapid recurrence and bilateral lungs, multible bone metastasis. Although intracranial MSFT is extremely rare, it should be considered in the differential diagnosis of tumors in CNS, and carful follow-up is needed. Definite diagnosis depended mainly on pathological morphology and immunohistochemistry.
Written informed consent was obtained from the patient for publication of this Case Report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
- Klemperer P, Coleman BR. Primary neoplasms of the pleura. A report of five cases. Am J Ind Med. 1992;22(1):1–31.PubMedView ArticleGoogle Scholar
- Kasper E, Boruchow S, Lam FC, Zinn PO, Anderson M, Mahadevan A. "Hitting all the right markers to save a life" Solitary fibrous tumors of the central nervous system: Case series and review of the literature. Surg Neurol Int. 2012;3:83.PubMed CentralPubMedView ArticleGoogle Scholar
- Fargen KM, Opalach KJ, Wakefield D, Jacob RP, Yachnis AT, Lister JR. The central nervous system solitary fibrous tumor: a review of clinical, imaging and pathologic findings among all reported cases from 1996 to 2010. Clin Neurol Neurosurg. 2011;113(9):703–10.PubMedView ArticleGoogle Scholar
- Ng HK, Choi PC, Wong CW, To KF, Poon WS. Metastatic solitary fibrous tumor of the meninges. Case report. J Neurosurg. 2000;93(3):490–93.PubMedView ArticleGoogle Scholar
- Barron J, Lownie SP, Lee DH, Hammond RR. 61 year old woman with confusion and obtundation. Brain Pathol 2001;11(4):485–86.PubMedView ArticleGoogle Scholar
- Martin AJ, Fisher C, Igbaseimokumo U, Jarosz JM, Dean AF. Solitary fibrous tumours of the meninges: case series and literature review. J Neurooncol 2001;54(1):57–9PubMedView ArticleGoogle Scholar
- Kim KA, Gonzalez I, McComb JG, Giannotta SL. Unusual presentations of cerebral solitary fibrous tumors: report of four cases. Neurosurgery 2004;54(4):1004–9PubMedView ArticleGoogle Scholar
- Miyashita K, Hayashi Y, Fujisawa H, Hasegawa M, Yamashita J. Recurrent intracranial solitary fibrous tumor with cerebrospinal fluid dissemination. Case report. J Neurosurg 2004;101(6):1045–48.PubMedView ArticleGoogle Scholar
- Ogawa K, Tada T, Takahashi S, Sugiyama N, Inaguma S, Takahashi SS, Shirai T. Malignant solitary fibrous tumor of the meninges. Virchows Arch 2004;444(5):459–64.PubMedView ArticleGoogle Scholar
- Pizem J, Matos B, Popovic M. Malignant intracranial solitary fibrous tumour with four recurrences over a 30-year period. Neuropathol Appl Neurobiol 2004;30(6):696–701.PubMedView ArticleGoogle Scholar
- Lawlor MW, Nielsen GP, Louis DN. Malignant solitary fibrous tumour of the meninges with marked amianthoid fibre deposition. Neuropathol Appl Neurobiol 2008;34(5):569–572.PubMedView ArticleGoogle Scholar
- Hu YC, Mahar TJ, Hicks DG, Raymond D, Jones C, Wandtke JC, et al. Malignant Solitary Fibrous Tumor Report of 3 Cases With Unusual Features. Appl Immunohistochem Mol Morphol. 2009;17:451–57.PubMedView ArticleGoogle Scholar
- Zhang J, Cheng H, Qiao Q, Zhang JS, Wang YM, Fu X, Li Q. Malignant solitary fibrous tumor arising from the pineal region: case study and literature review. Neuropathology 2010;30(3):294–98.PubMedView ArticleGoogle Scholar
- Choi CY, Han SR, Yee GT, Joo M. An intracranial malignant solitary fibrous tumor. Neuropathology. 2011;31:177–82.PubMedView ArticleGoogle Scholar
- Son S, Lee SG, Jeong DH, Yoo CJ. Malignant solitary fibrous tumor of tandem lesions in the skull and spine. J Korean Neurosurg Soc. 2013;54(3):246–49.PubMed CentralPubMedView ArticleGoogle Scholar
- Carneiro SS, Scheithauer BW, Nascimento AG, Hirose T, Davis DH. Solitary fibrous tumor of the meninges: a lesion distinct from fibrous meningioma. A clinicopathologic and immunohistochemical study. Am J Clin Pathol. 1996;106(2):217–24.PubMedGoogle Scholar
- Cummings TJ, Burchette JL, McLendon RE. CD34 and dural fibroblasts: the relationship to solitary fibrous tumor and meningioma. Acta Neuropathol. 2001;102(4):349–54.PubMedGoogle Scholar
- Metellus P, Bouvier C, Guyotat J, Fuentes S, Jouvet A, Vasiljevic A, et al. Solitary fibrous tumors of the central nervous system: clinicopathological and therapeutic considerations of 18 cases. Neurosurgery. 2007;60(4):715–22. discussion 722.PubMedView ArticleGoogle Scholar
- Guillou L, Fletcher JA, Fletcher CDM, Bridge JA, Lee J-C. Extrapleural soli-tary fibrous tumor and haemangiopericytoma. In: Fletcher CDM, Bridge JA, Hogendoorn PCW, Mertens F, editors. World Health Organization Classificationof Tumours. Pathology and Genetics of Tumours of Soft Tissue and Bone. Lyon, France: IARCPress; 2013. p. 80–2.Google Scholar
- Freiser ME, Castaño JE, Whittington EE, Arnold DJ, Sidani CA. Solitary Fibrous Tumor of the Infratemporal Fossa. Radiology Case. 2014;8(12):1–8.PubMed CentralPubMedGoogle Scholar
- Vogels R, Vlenterie M, Versleijen-Jonkers Y, Ruijter E, Bekers EM, Verdijk M, et al. Solitary fibrous tumor inverted question mark clinicopathologic, immunohistochemical and molecular analysis of 28 cases. Diagn Pathol. 2014;9(1):224.PubMed CentralPubMedView ArticleGoogle Scholar
- Bouvier C, Bertucci F, Metellus P, Finetti P, de Paula AM, Forest F, et al. ALDH1 is an immunohistochemical diagnostic marker for solitary fibrous tumours and haemangiopericytomas of the meninges emerging from gene profiling study. Acta Neuropathol Commun. 2013;1(1):10.PubMed CentralPubMedView ArticleGoogle Scholar
- Doyle LA, Vivero M, Fletcher CD, Mertens F, Hornick JL. Nuclear expression of STAT6 distinguishes solitary fibrous tumor from histologic mimics. Mod Pathol. 2014;27(3):390–95.PubMedGoogle Scholar
- Reames DL, Mohila CA, Sheehan JP. Treatment of intracranial solitary fibrous tumors with gamma knife radiosurgery: report of two cases and review of literature. Neurosurgery. 2011;69(4):E1023–1028. discussion E1028. PubMedView ArticleGoogle Scholar
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.